Gilead Sciences has announced an additional $11 billion in capital and operational investments in the US to supplement an already planned spend of $21 billion in US manufacturing and R&D through 2030.  

This next phase of investment will support the building of three new facilities, upgrading three existing sites to expand US manufacturing and R&D capabilities, and investing in new technology and advanced engineering initiatives. The additional $11 billion will cover:  

• $4 billion allocated to capital projects, including labs and equipment;

• $5 billion dedicated to technology, operations, and R&D site activities;

• $2 billion invested in digital and advanced engineering initiatives; and  

• Creation of approximately 800 new direct jobs and support for more than 2,200 indirect jobs by 2028. 

Source: Gilead Sciences